HYPOCRISY AND SHAME!

Discussion in 'Bausch & Lomb' started by anonymous, Apr 4, 2017 at 8:08 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Preet Bharara, the United States Attorney for the Southern District of New York, Diego Rodriguez, the Assistant Director-in-Charge of the New York Office of the Federal Bureau of Investigation (“FBI”), Gregory E. Demske, Chief Counsel to the Inspector General of the U.S. Department of Health and Human Services (“HHS-OIG”), and Scott J. Lampert, Special Agent in Charge of HHS-OIG’s New York Regional Office, announced a $390 million settlement against NOVARTIS Pharmaceuticals Corp.


    Government contends NOVARTIS violated the False Claims Act and the Anti-Kickback Statute, 42 U.S.C. § 1370a-7b, by giving kickbacks to specialty pharmacies in return for recommending Exjade, an iron chelation drug, and Myfortic, an anti-rejection drug for kidney transplant recipients.

    As the Government contended, evidence uncovered in the lawsuit shows that Exjade patient referrals were very valuable for pharmacies and that when it launched Exjade in 2005, NOVARTIS created a “closed distribution network” involving just three specialty pharmacies, BioScrip, Accredo, and US Bioservices. This gave NOVARTIS control over how many Exjade patients would be assigned to the pharmacies.

    As the Government contended, evidence uncovered in the lawsuit shows that Exjade patient referrals were very valuable for pharmacies and that when it launched Exjade in 2005, NOVARTIS created a “closed distribution network” involving just three specialty pharmacies, BioScrip, Accredo, and US Bioservices.


    More specifically, the Government alleged that, to increase Exjade sales, Novartis incentivized and pressured the pharmacies to emphasize Exjade’s benefits to patients while understating the drug’s serious, potentially life-threatening, side effects.

    With respect to Myfortic, the Government alleged that NOVARTIS gave rebate contracts to specialty pharmacies to induce the pharmacies to recommend to doctors that they switch patients to Myfortic from competitor drugs.

    Government contended NOVARTIS went forward with this scheme – which operated from 2008 to 2012 – even though it knew that the scheme presented risks of violating the Anti-Kickback Statute.


    Novartis did what Valeant had with only 1 specialty pharmacy called Phillidor and did it for 10 yrs, with multiple specialty pharmacies, which switched them to drugs with life life-threatening sideeffects and gave doctors kickbacks for prescribing their drug. Valeant did not even SCRATCH what Novartis did.


    And they settled for a measly $390 million with the DOJ. Philidor is a drop in a bucket, never switched any patients to dangerous drugs and Valeant bore a 100000000x the media shit storm that Novartis got. Not a single Phillidor costumer complained about the drugs they received from the pharmacy.

    HYPOCRISY!!

    SHAME!!

    SHAME ON YOU ALL!!
     

  2. anonymous

    anonymous Guest

    The market DESTROYED Valeant for having 1 small specialty pharmacy for 2 years called Phillidor and Novartis had 3 of them!! For a 10 yrs!! Not a single news agency covered it.

    Novartis was bribing doctors to prescribe their medicines!!
     
  3. anonymous

    anonymous Guest

    stuff a big banana in it, Jerry.
     
  4. anonymous

    anonymous Guest

    Wrong forum pal, the hypocrites hang out on CPValeant forum. They think they own B&L but haven't a clue,adios
     
  5. anonymous

    anonymous Guest

    oh stuff a big pickle up your pie hold dummy. Get positive
     
  6. anonymous

    anonymous Guest

    I like Pickles but not the Funk House kind, alright. I'll toss them back!